Jeff Yass’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-13,200
Closed -$88.6K – 12181
2024
Q1
$88.6K Buy
+13,200
New +$104K ﹤0.01% 11284
2023
Q4
– Sell
-26,000
Closed -$144K – 12477
2023
Q3
$144K Sell
26,000
-15,100
-37% -$121K ﹤0.01% 10593
2023
Q2
$351K Buy
+41,100
New +$369K ﹤0.01% 9122
2023
Q1
– Sell
-56,400
Closed -$576K – 12674
2022
Q4
$576K Buy
+56,400
New +$758K ﹤0.01% 7486

Other funds holding CTKB

Jeff Yass's CTKB Position: Q3 2026 in Review

Jeff Yass reduced its Cytek Biosciences (CTKB) stake by 93% in Q3 2026, selling an estimated $3M and leaving 48,634 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #11045.

Jeff Yass first reported a position in CTKB in Q1 2022 and has held it in 16 quarters since. The position peaked at $3.02M in Q2 2026. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Jeff Yass held 48,634 shares of Cytek Biosciences worth $290K as of Q3 2026.
  • Jeff Yass sold 633,071 Cytek Biosciences shares in Q3 2026, an estimated $3M.
  • Cytek Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #11045 holding.
  • Jeff Yass first reported a position in Cytek Biosciences in Q1 2022 and has held it in 16 quarters since.
  • Jeff Yass's Cytek Biosciences position peaked at $3.02M in Q2 2026.
  • 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.